Catalent, a contract development and manufacturing organization (CDMO), has announced a $12 million expansion program to increase biologics current good manufacturing practice (cGMP) analytical capabilities at its flagship facility in Kansas City, MO. The project will feature the addition of two new analytical development laboratories to support the growing demands of assay development for both traditional biologic and advanced biologic modality programs.
The first of the two new labs will cover approximately 3,500 square feet and are expected to be completed by the end of the month, with the second, measuring 3,000 square feet, expected to become operational in Q1 2023. The expansion will create approximately 50 new scientific jobs at the site by February of next year.
“The need for timely analytical support in development, characterization, and cGMP testing is critical for innovators across the biologics pipeline, with delays affecting the overall time to get new drugs into the clinic, and ultimately to patients,” says Jeremie Trochu, Catalent’s division head for bioanalytics. “Our team at Kansas City serves as a strategic partner for customers of all sizes, and this expansion will allow it to support the increased demand and assay requirements for broad-based and orthogonal analytical [chemistry, manufacturing, and controls] CMC services for both traditional biotherapeutics and advanced modalities, such as antibody-drug conjugates, cell and gene therapies, and mRNA vaccines.”